Since we launched this service four years ago, we have based our portfolio recommendations on how technology acts as a disruptor. These disruptive companies often apply technology to other industries to produce superior results. We’re taking that same theory and applying it to our own service by adding Igor Greenwald to the Breakthrough Tech Profits analyst team this month.

If you’re an Investing Daily Wealth Society member or a subscriber to MLP Profits or The Energy Strategist, then you are already familiar with Igor’s excellent work. Over the past four years, Igor has displayed a knack for recognizing opportunities in the market by identifying the right stocks to own and how to profit from them.

Igor’s addition to the BTP team couldn’t come at a better time. Although President Trump has been in office just two months, he’s already taken on the political establishment to advance his pro-growth economic agenda. Businesses also are feeling the disruption the president has caused, and we want to ensure that our readers aren’t blindsided by it.

With Trump decidedly pro-energy, Igor’s expertise in that area will enable him to ferret out the winners of what is shaping up to be the most exciting era in energy investing since the fracking revolution. Born in Ukraine, educated at Georgetown University and currently residing in western Massachusetts, Igor looks beyond Wall Street to analyze the global effect of U.S. economic policy.

In this issue Igor unveils his top technology play on the energy sector. Extracting oil and gas from the earth’s crust is a decidedly expensive and messy process, so a technology that can cut costs and reduce the environmental effects at the same time will attract a lot of investor interest. Igor has discovered a company with a fracking technology that gives it an edge on its competitors that the market hasn’t yet recognized.

As Joe Duarte reports about biotech, Trump’s proposed replacement for Obamacare will make it harder for smaller companies to obtain federal funding for developing revolutionary new treatments. For that reason, we are reluctantly closing out our two remaining plays in cancer immunotherapy.

Also because of shifting political winds, we’re taking profits in our “hidden gems.” One of these promising companies, which few analysts follow, already has delivered for us, and the other will have difficulty competing in an environment that favors less regulation. When Ben Shepherd added these two stocks six months ago, he assumed a Hillary Clinton presidency would push them higher, but under a Trump administration, both stocks will struggle so we’re moving our money into more promising sectors.

Lastly, I am closing out a couple of LEAPS option recommendations I made eight months ago at huge gains that have already exceeded their price targets. Although the LEAPS each have 10 months remaining, in this market we believe you’re better off booking target profits when you get them and moving on to the next great thing.